Tirzepatide is a dual GIP/GLP-1 receptor agonist designed to target the receptors for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It operates by enhancing insulin sensitivity, suppressing glucagon secretion, reducing appetite, and slowing gastric emptying. This compound is strictly intended for research purposes only and is not approved for human consumption. It should be handled and used by qualified professionals in a controlled laboratory setting.